First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastomaLinda M. Liau, Santosh Kesari, Keyoumars Ashkan et al.|Journal of Translational Medicine|2018Cited by 540
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent GlioblastomaLinda M. Liau, Lynne P. Taylor, Keyoumars Ashkan et al.|JAMA Oncology|2022Cited by 411
Non-viral precision T cell receptor replacement for personalized cell therapySusan P. Foy, Stefanie Mandl, James R. Heath et al.|Nature|2022Cited by 276
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade GliomaTimothy F. Cloughesy, Michael A. Vogelbaum, Kevin Petrecca et al.|JAMA Oncology|2020Cited by 141
LTBK-08. TOCA 511 & TOCA FC VERSUS STANDARD OF CARE IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMATimothy F. Cloughesy, Michael A. Vogelbaum, Kevin Petrecca et al.|Neuro-Oncology|2019Cited by 17